MedRx Statistics
Total Valuation
MedRx has a market cap or net worth of JPY 5.88 billion. The enterprise value is 4.12 billion.
| Market Cap | 5.88B |
| Enterprise Value | 4.12B |
Important Dates
The last earnings date was Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MedRx has 59.37 million shares outstanding. The number of shares has increased by 23.62% in one year.
| Current Share Class | 59.37M |
| Shares Outstanding | 59.37M |
| Shares Change (YoY) | +23.62% |
| Shares Change (QoQ) | +3.74% |
| Owned by Insiders (%) | 3.15% |
| Owned by Institutions (%) | 3.56% |
| Float | 56.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 45.92 |
| PB Ratio | 2.87 |
| P/TBV Ratio | 2.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.40 |
| EV / Sales | 32.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.25 |
Financial Position
The company has a current ratio of 23.69
| Current Ratio | 23.69 |
| Quick Ratio | 22.94 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.46% and return on invested capital (ROIC) is -27.94%.
| Return on Equity (ROE) | -44.46% |
| Return on Assets (ROA) | -26.57% |
| Return on Invested Capital (ROIC) | -27.94% |
| Return on Capital Employed (ROCE) | -45.29% |
| Weighted Average Cost of Capital (WACC) | 8.44% |
| Revenue Per Employee | 5.82M |
| Profits Per Employee | -42.59M |
| Employee Count | 22 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.15 |
Taxes
In the past 12 months, MedRx has paid 12.00 million in taxes.
| Income Tax | 12.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.92% in the last 52 weeks. The beta is 0.76, so MedRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +28.92% |
| 50-Day Moving Average | 111.78 |
| 200-Day Moving Average | 102.70 |
| Relative Strength Index (RSI) | 49.35 |
| Average Volume (20 Days) | 2,015,350 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedRx had revenue of JPY 128.00 million and -937.00 million in losses. Loss per share was -17.44.
| Revenue | 128.00M |
| Gross Profit | 126.00M |
| Operating Income | -942.00M |
| Pretax Income | -925.00M |
| Net Income | -937.00M |
| EBITDA | -929.00M |
| EBIT | -942.00M |
| Loss Per Share | -17.44 |
Balance Sheet
The company has 1.75 billion in cash and n/a in debt, giving a net cash position of 1.75 billion or 29.55 per share.
| Cash & Cash Equivalents | 1.75B |
| Total Debt | n/a |
| Net Cash | 1.75B |
| Net Cash Per Share | 29.55 |
| Equity (Book Value) | 2.05B |
| Book Value Per Share | 34.45 |
| Working Capital | 1.75B |
Cash Flow
In the last 12 months, operating cash flow was -888.00 million and capital expenditures -82.00 million, giving a free cash flow of -970.00 million.
| Operating Cash Flow | -888.00M |
| Capital Expenditures | -82.00M |
| Free Cash Flow | -970.00M |
| FCF Per Share | -16.34 |
Margins
| Gross Margin | 98.44% |
| Operating Margin | -735.94% |
| Pretax Margin | -722.66% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MedRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.62% |
| Shareholder Yield | -23.62% |
| Earnings Yield | -15.94% |
| FCF Yield | -16.50% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedRx has an Altman Z-Score of 25.21 and a Piotroski F-Score of 2.
| Altman Z-Score | 25.21 |
| Piotroski F-Score | 2 |